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Abstract
Background: Renal impairment (RI) is associated with impaired prognosis in patients with coronary artery disease. Clinical
and angiographic outcomes of patients undergoing percutaneous coronary intervention (PCI) with the use of drug-eluting
stents (DES) in this patient population are not well established.
Methods: We pooled individual data for 5,011 patients from 3 trials with the exclusive and unrestricted use of DES (SIRTAX -
N= 1,012, LEADERS - N= 1,707, RESOLUTE AC - N= 2,292). Angiographic follow-up was available for 1,544 lesions. Outcomes
through 2 years were stratified according to glomerular filtration rate (normal renal function: GFR$90 ml/min; mild RI: 90,
GFR$60 ml/min; moderate/severe RI GFR,60 ml/min).
Results: Patients with moderate/severe RI had an increased risk of cardiac death or myocardial infarction ([MI], OR 2.14,
95%CI 1.36–3.36), cardiac death (OR 2.21, 95%CI 1.10–4.46), and MI (OR 2.02, 95%CI 1.19–3.43) compared with patients with
normal renal function at 2 years follow-up. There was no difference in cardiac death or MI between patients with mild RI
compared to those with normal renal function (OR 1.10, 95%CI 0.75–1.61). The risk of target-lesion revascularization was
similar for patients with moderate/severe RI (OR 1.17, 95%CI 0.70–1.95) and mild RI (OR 1.16, 95%CI 0.81–1.64) compared
with patients with normal renal function. In-stent late loss and in-segment restenosis were not different for patients with
moderate/severe RI, mild RI, and normal renal function.
Conclusions: Renal function does not affect clinical and angiographic effectiveness of DES. However, prognosis remains
impaired among patients with moderate/severe RI.
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Introduction
The prevalence of chronic kidney disease continues to increase
worldwide, and the relationship between renal impairment (RI)
and risk of coronary artery disease is well established [1–3]. RI is
associated with a higher prevalence of coexisting cardiac risk
factors, particularly diabetes mellitus [4,5]. Patients with RI
typically present with advanced and more complex coronary
artery disease compared to patients without RI, as indicated by a
higher proportion of multivessel disease, left main disease, ostial
lesions, heavily calcified lesions, and lesions located in vein grafts
[1,4,5]. Noteworthy, cardiovascular disease accounts for over 50%
of mortality among patients with chronic kidney disease before
reaching end-stage renal disease [6].
RI has consistently been shown to adversely impact prognosis
among patients undergoing percutaneous coronary interventions
(PCI) by means of balloon angioplasty or bare metal stents [2,7,8].
Patients with RI have been found at increased risk for death,
myocardial infarction, and restenosis after bare metal stent
implantation compared with patients without RI [7,8]. The
advent of drug-eluting stents (DES) has improved clinical and
angiographic outcomes in most patient and lesion subsets [9].
However, data on DES implantation in patients with RI remain
scarce. Available reports are limited to registry-based series of
patients treated with bare-metal stents or DES [10–15], to
observational studies including specific patients subsets [11,16–
19], and to post-hoc analyses of randomized trials including
patients with relatively simple baseline clinical and angiographic
characteristics [17,18]. Previous reports of patients with RI
undergoing DES implantation have observed an increased risk
of mortality and myocardial infarction compared with patients
without RI. DES appear to mitigate the risk of restenosis among
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patients with RI [20], although it remains a matter of debate
whether the risk is similar to patients without renal impairment
[1]. Moreover, the impact of RI on the risk of stent thrombosis
(ST) after DES implantation is controversial [21–23]. Therefore,
we aimed to investigate the impact of RI on safety and
effectiveness of DES in a broad population of patients undergoing
PCI, by pooling 3 large-scale randomized controlled trials
investigating the exclusive and unrestricted use of DES for coronary
revascularization (ClinicalTrials.gov identifiers: NCT00297661,
NCT00389220, NCT00617084).
Methods
Study Population
Individual patient data were pooled for 5,011 patients from 3
randomized trials: the Sirolimus-Eluting and Paclitaxel-Eluting
Stent for Coronary Revascularization (SIRTAX) trial [24], the
Biolimus-Eluting Stent with Biodegradable Polymer versus
Sirolimus-Eluting Stent with Durable Polymer for Coronary
Revascularisation (LEADERS) trial [25], and the Comparison of
Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
(RESOLUTE All Comers) trial [26]. All trials were conducted
between 2004 and 2009 at European institutions, with the
exclusive use of DES and an all-comers study design. Inclusion
criteria were broad in order to reflect routine clinical practice.
Patients with either stable coronary artery disease or acute
coronary syndrome – including patients with unstable angina,
non-ST-segment elevation and ST-segment elevation myocardial
infarction – were eligible if they had at least one lesion with a
percent diameter stenosis of $50% in a vessel with reference
diameter of 2.25 to 4.0 mm (SIRTAX and RESOLUTE All
Comers) and 2.25 to 3.5 mm (LEADERS) [24–26]. None of the
trials had any restriction with respect to number of treated lesions,
treated vessels, lesion length, or number of stents implanted.
Exclusion criteria were few and included known intolerance to the
study drugs, metal alloys, or contrast media, planned surgery
within 6 months after the index procedure, and participation in
another study. Angiographic follow-up was planned at 8 months
among patients included in SIRTAX, at 9 months among 25% of
patients included in LEADERS, and at 13 months among 20% of
patients in RESOLUTE All Comers. The trials complied with the
provisions of the Declaration of Helsinki and the study protocols
were approved by the ethics committees at each study center
(University of Bern, Switzerland; Erasmus Medical Center,
Rotterdam, Netherlands; University Hospital Munich, Germany;
Herz-Kreislauf Zentrum, Segeberger Kliniken, Bad Segeberg,
Germany; Herzzentrum Leipzig, Leipzig, Germany; Hospital
Bogenhausen, Munich, Germany; Medical University of Silesia,
Katowice, Poland; Rigshospitalet, Copenhagen, Denmark; Med-
isch Centrum Leeuwarden, Leeuwarden, Netherlands; Onze Lieve
Vrouw Ziekenhuis, Aalst, Belgium; Hospital Universitario, Ma-
drid, Spain; Institut Cardiovasculaire Paris-Sud, Quincy, France;
Royal Brompton Hospital, London, UK; Royal Victoria Hospital,
Belfast, UK; Rabin Medical Center, Tel Aviv University, Israel;
Centro Cardiologico Monzino, Milan, Italy; University of Zurich,
Switzerland). All patients provided written informed consent for
participation in the study.
Table 1. Clinical Characteristics at Baseline.
Normal renal function Mild RI Moderate/Severe RI P
No. of patients 1819 2234 706
Age (y) 59.9 (10.4) 65.2 (10.1) 70.8 (9.3) ,0.001
Female 315 (17.3) 547 (24.5) 281 (39.8) ,0.001
Cardiac risk factors
Diabetes 373 (20.50) 460 (20.59) 262 (37.11) ,0.001
Insulin-requiring diabetes 94 (25.20) 160 (34.78) 126 (48.09) ,0.001
Obese 434 (23.93) 564 (25.40) 208 (29.50) 0.018
Hypertension 1170 (64.32) 1583 (70.86) 587 (83.15) ,0.001
Hypercholesterolaemia 1154 (63.44) 1495 (66.92) 462 (65.44) 0.13
Current smoking 665 (36.56) 523 (23.41) 106 (15.01) ,0.001
Clinical history
Previous MI 523 (29.16) 677 (30.55) 248 (35.32) 0.01
Previous PCI 517 (28.42) 710 (31.78) 252 (35.70) 0.01
Previous CABG 157 (8.63) 226 (10.12) 108 (15.30) ,0.001
Clinical presentation 0.98
Stable coronary artery disease 834 (45.58) 1052 (47.52) 352 (49.18)
NSTE-ACS 642 (35.22) 817 (36.68) 269 (37.92)
STEMI 343 (19.19) 365 (15.79) 85 (12.90)
LVEF ,0.50 249 (18.22) 315 (23.00) 156 (28.60) ,0.001
SYNTAX score 13.1 (8.3) 13.6 (8.8) 14.4 (9.2) 0.007
Multivessel disease 494 (27.16) 571 (25.59) 173 (24.50) 0.60
Values are means (SD) or n (%). CABG= coronary artery bypass graft, LVEF = left ventricular ejection fraction, MI =myocardial infarction, NSTE-ACS =non-ST segment
elevation acute coronary syndromes, PCI = percutaneous coronary intervention, RI = renal impairment, STEMI = ST-segement elevation myocardial infarction.
doi:10.1371/journal.pone.0106450.t001
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Procedures
Randomization was done after diagnostic angiography and
before PCI in all 3 trials. In the SIRTAX trial [24] patients were
randomly allocated to receive sirolimus-eluting stents (Cypher,
Cordis, Johnson & Johnson, Miami Lakes, FL) or paclitaxel-
eluting stents (Taxus, Boston Scientific, Natick, MA), in the
LEADERS trial [25] patients were randomly allocated to receive
biolimus-eluting stents (BioMatrix, Biosensors Inc, Newport
Beach, CA) or sirolimus-eluting stents (Cypher, Cordis, Johnson
& Jonhson, Miami Lakes, FL), and in the RESOLUTE All
Comers trial [26] patients were randomly allocated to receive
zotarolimus-eluting stents (Resolute, Medtronic Inc., Santa Rosa,
CA) or everolimus-eluting stents (Xience V, Abbott Vascular,
Santa Clara, CA). Balloon angioplasty and stent implantation were
performed according to standard techniques and in accordance
with guidelines [27]; direct stenting was allowed. Full lesion
coverage was attempted by implanting one or more stents. No
mixture of type of stents was permitted for a given patient unless
the operator was unable to insert the study stent, in which case
crossover to another device of the operator’s choice was possible.
In case of unplanned revascularization procedures requiring stent
implantation, in all 3 trials it was recommended that physicians
used the same type as the initially allocated study stent. Procedural
anticoagulation was achieved with unfractionated heparin at a
dose of 5,000 IU or 70 to 100 IU per kilogram of body weight; the
use of glycoprotein IIb/IIIa inhibitors was left to the operator’s
discretion. Dual antiplatelet therapy consisting of acetylsalicylic
acid of at least 75 mg once daily and the thienopyridine
clopidogrel 75 mg daily was prescribed for at least 12 months in
SIRTAX and LEADERS trials, and for at least 6 months in the
RESOLUTE All Comers trial.
Definitions
The primary safety endpoint of the present analysis was the
composite of cardiac death and myocardial infarction (MI) at 2
years. The primary effectiveness endpoint was clinically indicated
target-lesion revascularization (TLR) at 2 years. Secondary clinical
endpoints were the individual components of the primary safety
endpoint as well as all-cause death, the composite of all-cause
death and MI, clinically indicated target-vessel revascularization
(TVR), and definite and definite or probable stent thrombosis (ST)
according to the Academic Research Consortium criteria [28].
Table 2. Angiographic and Procedural Characteristics at Baseline.
Normal renal function Mild RI Moderate/Severe RI P
No. of patients 1819 2234 706
No. of vessels treated per patient 1.19 (0.40) 1.17 (0.44) 1.17 (0.44) 0.14
Allocated stent ,0.001
Sirolimus-eluting stent 477 (26.27) 619 (27.63) 201 (28.60)
Paclitaxel-eluting stent 227 (12.45) 220 (9.89) 55 (7.73)
Biolimus-eluting stent 254 (14.10) 399 (17.64) 151 (21.73)
Zotarolimus-eluting stent 425 (23.27) 496 (22.36) 151 (21.14)
Everolimus-eluting stent 436 (23.91) 500 (22.48) 148 (20.80)
No. of lesions 2647 3234 1015
No. of lesions treated per patient 1.45 (0.63) 1.44 (0.70) 1.44 (0.70) 0.49
Target vessel 0.81
Left main 46 (1.57) 40 (1.51) 19 (1.44)
Left anterior descending 1067 (40.40) 1302 (40.14) 401 (39.75)
Left circumflex 646 (24.25) 763 (23.87) 242 (23.43)
Right coronary artery 833 (31.96) 1056 (31.89) 309 (31.71)
Bypass graft 55 (1.82) 70 (2.59) 44 (3.66)
Lesion characteristics
De novo lesions 2470 (93.76) 2991 (93.17) 935 (92.54) 0.17
Total occlusion 382 (14.67) 393 (12.25) 100 (10.18) ,0.001
Moderate or severe calcification 521 (20.06) 677 (20.89) 212 (21.75) 0.24
Lesion length 12.89 (8.56) 12.56 (9.46) 12.24 (5.30) 0.05
RVD (mm) 2.74 (0.56) 2.68 (0.62) 2.63 (0.35) ,0.001
MLD (mm) 0.78 (0.50) 0.79 (0.55) 0.80 (0.31) 0.36
Stenosis (%) 71.15 (17.50) 70.19 (19.34) 69.22 (10.84) ,0.001
Stent characteristics
Number of stents per lesion 1.21 (0.64) 1.20 (0.70) 1.20 (0.39) 0.64
Average stent diameter 2.94 (0.41) 2.90 (0.46) 2.86 (0.26) ,0.001
Total stent length per lesion 20.62 (10.37) 20.55 (11.47) 20.49 (6.42) 0.75
Values are means (SD) or n (%). RVD= reference vessel diameter, MLD=minimal lumen diameter, RI = renal impairment.
doi:10.1371/journal.pone.0106450.t002
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For each trial, a blinded clinical events committee indepen-
dently adjudicated all adverse events. Endpoint definitions were
comparable across the 3 trials. Cardiac death was defined as death
from cardiac causes or any death from unknown causes in
SIRTAX and LEADERS, and as any death unless an undisputed
non-cardiac cause was present in RESOLUTE All Comers. MI
was defined – in SIRTAX and LEADERS trials – as the presence
of new Q waves in at least two contiguous leads and an elevated
creatine kinase MB fraction, or – in the absence of significant Q
waves – as an increase in the creatine kinase level to more than
twice the upper limit of the normal range with an elevated level of
creatine kinase MB or troponin [24,25]. In the RESOLUTE All
Comers trial MI was defined according to an ‘‘extended historical’’
definition consistent with the one used in SIRTAX and
LEADERS [26,29]. Target-lesion revascularization was defined
as any revascularization for a stenosis within the stent or within a
5 mm border proximal and distal to the stent in all 3 trials. A
revascularization was considered clinically indicated in the
presence of angiographic diameter stenosis of at least 50% and
ischemic signs or symptoms, or with angiographic diameter
stenosis of at least 70% regardless of ischemic signs or symptoms
[24–26].
Secondary angiographic endpoints were late lumen loss (i.e.,
difference between the post-procedure and follow-up minimal
lumen diameter), rate of binary restenosis (i.e., % diameter stenosis
of at least 50%), percent diameter stenosis (i.e., reference vessel
diameter - minimal lumen diameter/reference vessel diameter x
100), and minimal lumen diameter. Angiographic endpoints were
considered for both the in-stent (i.e., within the stent) and in-
segment (i.e., within the stent and a 5 mm border proximal and
distal) analyses. For a detailed description of quantitative coronary
angiography methods we refer to the principal publications of the
3 trials [24–26].
Glomerular filtration rate (GFR) was estimated by the use of the
Modification of Diet in Renal Disease (MDRD) equation [30].
Patients were stratified in 3 groups according to the estimated
GFR at the time of hospital admission, based on chronic kidney
disease staging of the National Kidney Foundation (i.e., normal
renal function: GFR$90 ml/min; mild RI: 90.GFR$60 ml/
min; moderate/severe RI GFR,60 ml/min) [30].
Statistical analysis
Patients with mild and patients with moderate/severe RI were
compared to patients with normal renal function, respectively.
Comparison between groups were carried out using mixed models
with random effects specified as type of randomized clinical trial as
random intercept and treatment arms as random coefficients.
Mixed maximum logistic regression models were used to derive
differences between groups for binary and continuous outcomes.
Percentages were predicted probabilities derived from mixed
maximum logistic regression models. Means and standard
deviations were predicted values derived from mixed maximum
likelihood regression models. Odds ratios (OR) and confidence
intervals (CI) were adjusted for stent type in the crude analysis
while the adjusted analysis was performed using multivariable
models, adjusting for baseline variables showing differences (P,
0.1) between groups including: stent type, age, gender, diabetes,
body mass index, hypertension, current smoking, previous MI,
previous PCI, previous coronary artery bypass grafting, left
ventricular ejection fraction ,50%, and syntax score. In addition,
predicted OR for cardiac death or MI and TLR at different levels
of GFR (using 90 ml/min as reference) were calculated. Analyses
were performed using STATA 11.0 (StataCorp, College Station,
TX). P-values ,0.05 were considered statistically significant.
Results
Out of 5,011 patients included in the 3 trials, 4,759 (95.0%)
patients completed 2 years of follow-up and are part of the present
analysis. Of these, 1,819 (38.2%) patients had normal renal
function, 2,234 (47.0%) patients had mild RI, and 706 (14.8%)
patients had moderate/severe RI at the time of hospital admission.
Baseline clinical characteristics are presented in Table 1.
Patients with any RI were older (P,0.001), more frequently
women (P,0.001) and obese (P= 0.018), had more frequently
diabetes (P,0.001), hypertension (P,0.001), a left ventricular
ejection fraction ,50%, and a clinical history of MI (P= 0.01),
previous PCI (P= 0.01), or coronary artery bypass grafting (P,
0.001), had less frequently smoking habits (P,0.001), and a higher
angiographic complexity of disease as assessed by Syntax score
(P= 0.007) compared with patients with normal renal function.
Angiographic and procedural characteristics are summarized in
Table 2. Patients with RI had less frequently total occlusions (P,
0.001), smaller diameter of the reference vessel (P,0.001) and
stent diameter (P,0.001), and a lower percent diameter stenosis
(P,0.001) compared with patients with normal renal function.
Safety Outcomes
Crude and adjusted clinical outcomes through 2 years are
presented in Table 3. At 2 years, patients with moderate/severe
RI experienced a higher risk of the primary safety composite of
cardiac death or MI (adjusted OR=2.14, 95%CI 1.36–3.36, P,
Figure 1. Predicted Risk of Adverse Clinical Outcomes According to Renal Function. Crude and adjusted predicted 2-year odds ratios for
the composite of cardiac death and myocardial infarction (left) and target-lesion revascularization (right) at different levels of baseline glomerular
filtration rate (GFR), using 90 ml/min as reference.
doi:10.1371/journal.pone.0106450.g001
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0.001), as well as cardiac death (adjusted OR=2.21, 95%CI 1.10–
4.46, P= 0.03) and MI (adjusted OR=2.02, 95%CI 1.19–3.43,
P= 0.01) compared with patients with normal renal function in
crude and adjusted analyses. Patients with mild renal impairment
had similar risks of cardiac death or MI (adjusted OR=1.10,
95%CI 0.75–1.61, P= 0.62), cardiac death (adjusted OR=0.99,
95%CI 0.52–1.89, P= 0.97), and MI (adjusted OR=1.08, 95%CI
0.70–1.66, P= 0.74) compared with patients with normal renal
function in crude and adjusted analyses. Predicted odds ratios
according to GFR for the primary safety composite endpoint of
cardiac death and MI are shown in Figure 1a. There was an
inverse near linear relationship between GFR below 60 and the
predicted OR of cardiac death or MI in crude and adjusted
analyses.
The risk of ST did not differ between patients with moderate/
severe RI (definite ST: adjusted OR 1.39, 95%CI 0.58–3.33,
P= 0.46; definite or probable ST: 1.60; adjusted OR 1.60, 95%CI
0.76–3.39, P= 0.22) as well as patients with mild RI (definite ST:
adjusted OR 0.92, 95%CI 0.47–1.78, P= 0.80; definite or
probable ST: 1.60; adjusted OR 1.00, 95%CI 0.55–1.80,
P= 1.00) compared with patients with normal renal function
(Table 4). Similarly, no differences between groups were
observed in rates of ST during the early (0–30 days), late (31
days-1 year), and very late (.1 year) follow-up period.
Effectiveness Outcomes
The risk of repeat revascularization did not differ between
patients with moderate/severe RI, mild RI and those with normal
renal function, in terms of both TLR (moderate/severe RI vs.
normal renal function adjusted OR=1.17, 95%CI 0.70–1.95,
P= 0.55; mild RI vs. normal renal function adjusted OR=1.16,
95%CI 0.81–1.64, P= 0.42) and TVR (moderate/severe RI vs.
normal renal function adjusted OR=0.99, 95%CI 0.62–1.61,
P= 0.98; mild vs. normal renal function adjusted OR=1.08,
95%CI 0.78–1.48, P= 0.65) at 2 years.
Predicted OR according to GFR for the primary effectiveness
endpoint TLR are shown in Figure 1b. Decreasing GFR did not
adversely impact the odds of TLR in crude and adjusted analyses.
Angiographic surveillance was performed in 1,123 patients with
1,544 lesions, and angiographic findings are presented in
Table 5. No differences were observed between patients with
moderate/severe RI and patients with mild RI compared with
patients with normal renal function in terms of in-stent late loss
(normal renal function = 0.1960.65 mm, mild RI= 0.196
0.69 mm, moderate/severe RI= 0.1860.53 mm) and in-segment
binary restenosis (normal renal function = 7.9%, mild RI= 8.1%,
moderate/severe RI= 11.2%). Figure 2 depicts the cumulative
frequency of in-stent late lumen loss for lesions among patients
with moderate/severe and mild RI and normal renal function.
Discussion
The present analysis of individual patient data from three large
randomized controlled trials with the unrestricted use of DES
investigating the impact of baseline renal function on long-term
clinical and angiographic outcomes through 2 years has the
following findings:
1) In this large all-comers patient population, the majority of
patients had some degree of renal impairment with nearly half
of patients suffering from mild RI and 15% of patients
suffering from moderate/severe RI
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2) Patients with moderate/severe RI undergoing PCI with DES
had a 2-fold increased risk of cardiac death and MI as
compared to patients with normal renal function
3) Device-specific safety as assessed by the endpoint stent
thrombosis was not influenced by renal function and resulted
in low and similar risks of ST irrespective of RI at baseline
4) The effectiveness of DES was largely unaffected by renal
function and resulted in low and similar risks of repeat
revascularization as well as angiographic outcomes irrespec-
tive of RI at baseline
Patients with impaired renal function undergoing PCI have a
higher cardiovascular risk profile at baseline as well as more
complex and advanced coronary artery disease. Several previous
reports have pointed to impaired clinical outcomes among patients
with RI [7]. Thus, RI has been associated with an increased risk of
in-hospital and long-term adverse events in the balloon angioplasty
era [31,32]. Although the advent of bare metal stents improved
procedural success rates, patients with RI remained at increased
risk of death and MI as well as restenosis during long-term follow-
up [4,7,8]. DES have improved effectiveness by reducing the need
for repeat revascularization and are used in the majority of
patients undergoing PCI today [33,34]. Notwithstanding, the
impact of RI on clinical outcomes among patients undergoing
DES implantation are limited to registry-based investigations [10–
12,14,15], or to specific subsets of patients such as the elderly [11],
patients with acute myocardial infarction [16], or patients with
simple baseline clinical and angiographic characteristics [17,18].
Against this background, we investigated the impact of RI on long-
term clinical and angiographic outcomes in a patient-level pooled
analysis of three large randomized trials with the unrestricted use
of DES.
Our study corroborates the findings of previous reports and
indicates that the risk of cardiac death and MI is 2-fold increased
among patients with moderate/severe RI [11,14–16]. This risk
reflects the higher complexity and baseline risk profile of patients
with moderate/severe RI, and its persistence after adjustment for
baseline differences highlights the independent negative impact of
RI on patients’ prognosis. Coronary artery disease progression,
myocardial structural changes with subsequent systolic and
diastolic dysfunction, electrolyte imbalance, and autonomic
dysfunction have been identified as major contributors of
increased risk of cardiovascular adverse events in patients with
RI [1,35].
Of note, the risk of ST was unaffected by baseline renal
function. Therefore, the increased risk of cardiac death or MI is
not related to device-specific issues but rather to disease-specific
changes in the individual patient risk profile. These findings
suggest that patients with impaired renal function might benefit
from a more intense medical therapy and a careful follow-up
aiming at preventing coronary artery disease progression after
percutaneous revascularization.
Similarly, the risk of repeat revascularization as assessed by
TLR and TVR did not differ between patients with moderate/
severe RI, mild RI, and normal renal function suggesting that
neointimal hyperplasia is potently suppressed by DES independent
of baseline renal function. This observation is supported by the
findings of quantitative coronary angiography during angiographic
follow-up surveillance indicating a similar cumulative frequency of
in-stent late loss in all three groups. In summary, these findings
indicate that the DES effectiveness is not affected by renal
function.
This study has the following limitations. First, it is a pooled
analysis from 3 randomized clinical trials not primarily intended to
investigate differences in outcomes according to renal function at
baseline. However, the large number of patients provides
reasonable precision to evaluate differences between subjects with
different stages of renal function in a wide spectrum of patients
with clinical presentations ranging from stable coronary artery
disease to acute myocardial infarction. Second, 5 different types of
DES were used in the three trials included in the present analysis.
We therefore analyzed differences using mixed models accounting
for different trials as well as treatment arms. Moreover, the use of
different types of DES afford a certain generalizability of our
findings to DES as a class treatment effect. Third, only 63 patients
(1.3%) had a GFR,30 ml/min at baseline and patients requiring
hemodialysis were not captured in the pooled trials. Evaluation of
the safety and effectiveness of DES in patients with severely
impaired renal function and in those requiring hemodialysis will
certainly prompt additional investigations. Fourth, bleeding events
were not captured in the three pooled trials. Therefore, we were
not able to compared bleeding risks between groups. Finally, the
angiographic follow-up was not available for all included patients.
Nevertheless, the consistency of angiographic surveillance findings
and the correlation with clinical outcomes support our finding of
equivalent effectiveness of DES in patients with coronary artery
disease undergoing PCI regardless of renal function.
Conclusions
Patients with moderate/severe RI undergoing PCI with the
unrestricted use of DES have a 2-fold increased risk of cardiac
death and MI as compared to patients with normal renal function.
DES effectively mitigate neointimal hyperplasia and afford a
similar clinical and angiographic effectiveness among patients with
RI as compared to those with normal renal function.
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Figure 2. Angiographic Effectiveness. Cumulative frequency of in-
stent late lumen loss at the time of follow-up angiography according to
baseline renal function. RI = Renal impairment.
doi:10.1371/journal.pone.0106450.g002
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